1
|
Coates RJ, Young MT, Scofield S. Optimising expression and extraction of recombinant proteins in plants. FRONTIERS IN PLANT SCIENCE 2022; 13:1074531. [PMID: 36570881 PMCID: PMC9773421 DOI: 10.3389/fpls.2022.1074531] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 11/22/2022] [Indexed: 06/17/2023]
Abstract
Recombinant proteins are of paramount importance for research, industrial and medical use. Numerous expression chassis are available for recombinant protein production, and while bacterial and mammalian cell cultures are the most widely used, recent developments have positioned transgenic plant chassis as viable and often preferential options. Plant chassis are easily maintained at low cost, are hugely scalable, and capable of producing large quantities of protein bearing complex post-translational modification. Several protein targets, including antibodies and vaccines against human disease, have been successfully produced in plants, highlighting the significant potential of plant chassis. The aim of this review is to act as a guide to producing recombinant protein in plants, discussing recent progress in the field and summarising the factors that must be considered when utilising plants as recombinant protein expression systems, with a focus on optimising recombinant protein expression at the genetic level, and the subsequent extraction and purification of target proteins, which can lead to substantial improvements in protein stability, yield and purity.
Collapse
|
2
|
Ruiz-Molina N, Parsons J, Schroeder S, Posten C, Reski R, Decker EL. Process Engineering of Biopharmaceutical Production in Moss Bioreactors via Model-Based Description and Evaluation of Phytohormone Impact. Front Bioeng Biotechnol 2022; 10:837965. [PMID: 35252145 PMCID: PMC8891706 DOI: 10.3389/fbioe.2022.837965] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 01/24/2022] [Indexed: 12/24/2022] Open
Abstract
The moss Physcomitrella is an interesting production host for recombinant biopharmaceuticals. Here we produced MFHR1, a synthetic complement regulator which has been proposed for the treatment of diseases associated to the complement system as part of human innate immunity. We studied the impact of different operation modes for the production process in 5 L stirred-tank photobioreactors. The total amount of recombinant protein was doubled by using fed-batch or batch compared to semi-continuous operation, although the maximum specific productivity (mg MFHR1/g FW) increased just by 35%. We proposed an unstructured kinetic model which fits accurately with the experimental data in batch and semi-continuous operation under autotrophic conditions with 2% CO2 enrichment. The model is able to predict recombinant protein production, nitrate uptake and biomass growth, which is useful for process control and optimization. We investigated strategies to further increase MFHR1 production. While mixotrophic and heterotrophic conditions decreased the MFHR1-specific productivity compared to autotrophic conditions, addition of the phytohormone auxin (NAA, 10 µM) to the medium enhanced it by 470% in shaken flasks and up to 230% and 260%, in batch and fed-batch bioreactors, respectively. Supporting this finding, the auxin-synthesis inhibitor L-kynurenine (100 µM) decreased MFHR1 production significantly by 110% and 580% at day 7 and 18, respectively. Expression analysis revealed that the MFHR1 transgene, driven by the Physcomitrella actin5 (PpAct5) promoter, was upregulated 16 h after NAA addition and remained enhanced over the whole process, whereas the auxin-responsive gene PpIAA1A was upregulated within the first 2 hours, indicating that the effect of auxin on PpAct5 promoter-driven expression is indirect. Furthermore, the day of NAA supplementation was crucial, leading to an up to 8-fold increase of MFHR1-specific productivity (0.82 mg MFHR1/g fresh weight, 150 mg accumulated over 7 days) compared to the productivity reported previously. Our findings are likely to be applicable to other plant-based expression systems to increase biopharmaceutical production and yields.
Collapse
Affiliation(s)
- Natalia Ruiz-Molina
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Juliana Parsons
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Sina Schroeder
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Clemens Posten
- Institute of Process Engineering in Life Sciences III Bioprocess Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany
| | - Ralf Reski
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
- Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany
| | - Eva L. Decker
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
- *Correspondence: Eva L. Decker,
| |
Collapse
|
3
|
Ghag SB, Adki VS, Ganapathi TR, Bapat VA. Plant Platforms for Efficient Heterologous Protein Production. BIOTECHNOL BIOPROC E 2021; 26:546-567. [PMID: 34393545 PMCID: PMC8346785 DOI: 10.1007/s12257-020-0374-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Revised: 01/14/2021] [Accepted: 01/16/2021] [Indexed: 02/07/2023]
Abstract
Production of recombinant proteins is primarily established in cultures of mammalian, insect and bacterial cells. Concurrently, concept of using plants to produce high-value pharmaceuticals such as vaccines, antibodies, and dietary proteins have received worldwide attention. Newer technologies for plant transformation such as plastid engineering, agroinfiltration, magnifection, and deconstructed viral vectors have been used to enhance the protein production in plants along with the inherent advantage of speed, scale, and cost of production in plant systems. Production of therapeutic proteins in plants has now a more pragmatic approach when several plant-produced vaccines and antibodies successfully completed Phase I clinical trials in humans and were further scheduled for regulatory approvals to manufacture clinical grade products on a large scale which are safe, efficacious, and meet the quality standards. The main thrust of this review is to summarize the data accumulated over the last two decades and recent development and achievements of the plant derived therapeutics. It also attempts to discuss different strategies employed to increase the production so as to make plants more competitive with the established production systems in this industry.
Collapse
Affiliation(s)
- Siddhesh B. Ghag
- School of Biological Sciences, UM-DAE Centre for Excellence in Basic Sciences, University of Mumbai campus, Kalina, Santacruz, Mumbai, 400098 India
| | - Vinayak S. Adki
- V. G. Shivdare College of Arts, Commerce and Science, Solapur, Maharashtra 413004 India
| | - Thumballi R. Ganapathi
- Plant Cell Culture Technology Section, Nuclear Agriculture & Biotechnology Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085 India
| | - Vishwas A. Bapat
- Department of Biotechnology, Shivaji University, Vidyanagar, Kolhapur, Maharashtra 416004 India
| |
Collapse
|
4
|
Campos ML, Prado GS, Dos Santos VO, Nascimento LC, Dohms SM, da Cunha NB, Ramada MHS, Grossi-de-Sa MF, Dias SC. Mosses: Versatile plants for biotechnological applications. Biotechnol Adv 2020; 41:107533. [PMID: 32151692 DOI: 10.1016/j.biotechadv.2020.107533] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Revised: 02/11/2020] [Accepted: 02/12/2020] [Indexed: 02/03/2023]
Abstract
Mosses have long been recognized as powerful experimental tools for the elucidation of complex processes in plant biology. Recent increases in the availability of sequenced genomes and mutant collections, the establishment of novel technologies for targeted mutagenesis, and the development of viable protocols for large-scale production in bioreactors are now transforming mosses into one of the most versatile tools for biotechnological applications. In the present review, we highlight the astonishing biotechnological potential of mosses and how these plants are being exploited for industrial, pharmaceutical, and environmental applications. We focus on the biological features that support their use as model organisms for basic and applied research, and how these are being leveraged to explore the biotechnological potential in an increasing number of species. Finally, we also provide an overview of the available moss cultivation protocols from an industrial perspective, offering insights into batch operations that are not yet well established or do not even exist in the literature. Our goal is to bolster the use of mosses as factories for the biosynthesis of molecules of interest and to show how these species can be harnessed for the generation of novel and commercially useful bioproducts.
Collapse
Affiliation(s)
- Marcelo Lattarulo Campos
- Integrative Plant Research Laboratory, Departamento de Botânica e Ecologia, Instituto de Biociências, Universidade Federal de Mato Grosso, Cuiabá, MT, Brazil.
| | - Guilherme Souza Prado
- Laboratório de Interação Molecular Planta-Praga, Embrapa Recursos Genéticos e Biotecnologia, Brasília, DF, Brazil; Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil
| | - Vanessa Olinto Dos Santos
- Laboratório de Interação Molecular Planta-Praga, Embrapa Recursos Genéticos e Biotecnologia, Brasília, DF, Brazil
| | - Lara Camelo Nascimento
- Centro de Análises Bioquímicas e Proteômicas, Universidade Católica de Brasília, Brasilia, DF, Brazil
| | - Stephan Machado Dohms
- Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil.
| | - Nicolau Brito da Cunha
- Centro de Análises Bioquímicas e Proteômicas, Universidade Católica de Brasília, Brasilia, DF, Brazil; Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil
| | - Marcelo Henrique Soller Ramada
- Centro de Análises Bioquímicas e Proteômicas, Universidade Católica de Brasília, Brasilia, DF, Brazil; Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil.
| | - Maria Fatima Grossi-de-Sa
- Laboratório de Interação Molecular Planta-Praga, Embrapa Recursos Genéticos e Biotecnologia, Brasília, DF, Brazil; Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil.
| | - Simoni Campos Dias
- Centro de Análises Bioquímicas e Proteômicas, Universidade Católica de Brasília, Brasilia, DF, Brazil; Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brazil; Programa de Pós-Graduação em Biologia Animal, Universidade de Brasília, Campus Darcy Ribeiro, Brasília, DF, Brazil.
| |
Collapse
|
5
|
Phan TLCHB, Delorge I, Avonce N, Van Dijck P. Functional Characterization of Class I Trehalose Biosynthesis Genes in Physcomitrella patens. FRONTIERS IN PLANT SCIENCE 2020; 10:1694. [PMID: 32038675 PMCID: PMC6984353 DOI: 10.3389/fpls.2019.01694] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Accepted: 11/29/2019] [Indexed: 06/10/2023]
Abstract
The function of trehalose metabolism in plants during growth and development has been extensively studied, mostly in the eudicot Arabidopsis thaliana. So far, however, not much is known about trehalose metabolism in the moss Physcomitrella patens. Here, we show that in P. patens, two active trehalose-6-phosphate synthase enzymes exist, PpTPS1 and PpTPS2. Expression of both enzymes in Saccharomyces cerevisiae can complement the glucose-growth defect of the yeast tps1∆ mutant. Truncation of N-terminal extension in PpTPS1 and PpTPS2 resulted in higher TPS activity and high trehalose levels, upon expression in yeast. Physcomitrella knockout plants were generated and analyzed in various conditions to functionally characterize these proteins. tps1∆ and tps2∆ knockouts displayed a lower amount of caulonema filaments and were significantly reduced in size of gametophores as compared to the wild type. These phenotypes were more pronounced in the tps1∆ tps2∆ mutant. Caulonema formation is induced by factors such as high energy and auxins. Only high amounts of supplied energy were able to induce caulonema filaments in the tps1∆ tps2∆ mutant. Furthermore, this mutant was less sensitive to auxins as NAA-induced caulonema development was arrested in the tps1∆ tps2∆ mutant. In contrast, formation of caulonema filaments is repressed by cytokinins. This effect was more severe in the tps1∆ and tps1∆ tps2∆ mutants. Our results demonstrate that PpTPS1 and PpTPS2 are essential for sensing and signaling sugars and plant hormones to monitor the balance between caulonema and chloronema development.
Collapse
Affiliation(s)
- Tran Le Cong Huyen Bao Phan
- VIB-KU Leuven Center for Microbiology, VIB, Leuven, Belgium
- Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium
- Department of Biology, College of Natural Sciences, Cantho University, Cantho, Vietnam
| | - Ines Delorge
- VIB-KU Leuven Center for Microbiology, VIB, Leuven, Belgium
- Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium
| | - Nelson Avonce
- VIB-KU Leuven Center for Microbiology, VIB, Leuven, Belgium
- Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium
- Centro de Investigación en Dinámica Celular, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico
| | - Patrick Van Dijck
- VIB-KU Leuven Center for Microbiology, VIB, Leuven, Belgium
- Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium
| |
Collapse
|
6
|
Top O, Parsons J, Bohlender LL, Michelfelder S, Kopp P, Busch-Steenberg C, Hoernstein SNW, Zipfel PF, Häffner K, Reski R, Decker EL. Recombinant Production of MFHR1, A Novel Synthetic Multitarget Complement Inhibitor, in Moss Bioreactors. FRONTIERS IN PLANT SCIENCE 2019; 10:260. [PMID: 30949184 PMCID: PMC6436476 DOI: 10.3389/fpls.2019.00260] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Accepted: 02/19/2019] [Indexed: 05/23/2023]
Abstract
The human complement system is an important part of the immune system responsible for lysis and elimination of invading microorganisms and apoptotic body cells. Improper activation of the system due to deficiency, mutations, or autoantibodies of complement regulators, mainly factor H (FH) and FH-related proteins (FHRs), causes severe kidney and eye diseases. However, there is no recombinant FH therapeutic available on the market. The first successful recombinant production of FH was accomplished with the moss bioreactor, Physcomitrella patens. Recently, a synthetic regulator, MFHR1, was designed to generate a multitarget complement inhibitor that combines the activities of FH and the FH-related protein 1 (FHR1). The potential of MFHR1 was demonstrated in a proof-of-concept study with transiently transfected insect cells. Here, we present the stable production of recombinant glyco-engineered MFHR1 in the moss bioreactor. The key features of this system are precise genome engineering via homologous recombination, Good Manufacturing Practice-compliant production in photobioreactors, high batch-to-batch reproducibility, and product stability. Several potential biopharmaceuticals are being produced in this system. In some cases, these are even biobetters, i.e., the recombinant proteins produced in moss have a superior quality compared to their counterparts from mammalian systems as for example moss-made aGal, which successfully passed phase I clinical trials. Via mass spectrometry-based analysis of moss-produced MFHR1, we now prove the correct synthesis and modification of this glycoprotein with predominantly complex-type N-glycan attachment. Moss-produced MFHR1 exhibits cofactor and decay acceleration activities comparable to FH, and its mechanism of action on multiple levels within the alternative pathway of complement activation led to a strong inhibitory activity on the whole alternative pathway, which was higher than with the physiological regulator FH.
Collapse
Affiliation(s)
- Oguz Top
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
- Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, Freiburg, Germany
| | - Juliana Parsons
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Lennard L. Bohlender
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Stefan Michelfelder
- Faculty of Medicine, Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center - University Freiburg, University of Freiburg, Freiburg, Germany
| | - Phillipp Kopp
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| | | | | | - Peter F. Zipfel
- Leibniz Institute for Natural Product Research and Infection Biology, Friedrich Schiller University, Jena, Germany
| | - Karsten Häffner
- Faculty of Medicine, Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center - University Freiburg, University of Freiburg, Freiburg, Germany
| | - Ralf Reski
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
- Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, Freiburg, Germany
- Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany
| | - Eva L. Decker
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| |
Collapse
|
7
|
Hoernstein SNW, Fode B, Wiedemann G, Lang D, Niederkrüger H, Berg B, Schaaf A, Frischmuth T, Schlosser A, Decker EL, Reski R. Host Cell Proteome of Physcomitrella patens Harbors Proteases and Protease Inhibitors under Bioproduction Conditions. J Proteome Res 2018; 17:3749-3760. [PMID: 30226384 DOI: 10.1021/acs.jproteome.8b00423] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Host cell proteins are inevitable contaminants of biopharmaceuticals. Here, we performed detailed analyses of the host cell proteome of moss ( Physcomitrella patens) bioreactor supernatants using mass spectrometry and subsequent bioinformatics analysis. Distinguishing between the apparent secretome and intracellular contaminants, a complex extracellular proteolytic network including subtilisin-like proteases, metallo-proteases, and aspartic proteases was identified. Knockout of a subtilisin-like protease affected the overall extracellular proteolytic activity. Besides proteases, also secreted protease-inhibiting proteins such as serpins were identified. Further, we confirmed predicted cleavage sites of 40 endogenous signal peptides employing an N-terminomics approach. The present data provide novel aspects to optimize both product stability of recombinant biopharmaceuticals as well as their maturation along the secretory pathway. Data are available via ProteomeXchange with identifier PXD009517.
Collapse
Affiliation(s)
- Sebastian N W Hoernstein
- Plant Biotechnology, Faculty of Biology , University of Freiburg , Schaenzlestrasse 1 , D-79104 Freiburg , Germany
| | - Benjamin Fode
- Greenovation Biotech GmbH , Hans-Bunte-Strasse 19 , D-79108 Freiburg , Germany
| | - Gertrud Wiedemann
- Plant Biotechnology, Faculty of Biology , University of Freiburg , Schaenzlestrasse 1 , D-79104 Freiburg , Germany
| | - Daniel Lang
- Plant Biotechnology, Faculty of Biology , University of Freiburg , Schaenzlestrasse 1 , D-79104 Freiburg , Germany.,Plant Genome and System Biology , Helmholtz Center Munich , D-85764 Neuherberg , Germany
| | - Holger Niederkrüger
- Greenovation Biotech GmbH , Hans-Bunte-Strasse 19 , D-79108 Freiburg , Germany
| | - Birgit Berg
- Greenovation Biotech GmbH , Hans-Bunte-Strasse 19 , D-79108 Freiburg , Germany
| | - Andreas Schaaf
- Greenovation Biotech GmbH , Hans-Bunte-Strasse 19 , D-79108 Freiburg , Germany
| | - Thomas Frischmuth
- Greenovation Biotech GmbH , Hans-Bunte-Strasse 19 , D-79108 Freiburg , Germany
| | - Andreas Schlosser
- Rudolf-Virchow-Center for Experimental Biomedicine , University of Wuerzburg , D-97080 Wuerzburg , Germany
| | - Eva L Decker
- Plant Biotechnology, Faculty of Biology , University of Freiburg , Schaenzlestrasse 1 , D-79104 Freiburg , Germany
| | - Ralf Reski
- Plant Biotechnology, Faculty of Biology , University of Freiburg , Schaenzlestrasse 1 , D-79104 Freiburg , Germany.,BIOSS - Centre for Biological Signalling Studies , University of Freiburg , D-79104 Freiburg , Germany
| |
Collapse
|
8
|
Reski R, Bae H, Simonsen HT. Physcomitrella patens, a versatile synthetic biology chassis. PLANT CELL REPORTS 2018; 37:1409-1417. [PMID: 29797047 DOI: 10.1007/s00299-018-2293-6] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Accepted: 05/11/2018] [Indexed: 05/21/2023]
Abstract
During three decades the moss Physcomitrella patens has been developed to a superb green cell factory with the first commercial products on the market. In the past three decades the moss P. patens has been developed from an obscure bryophyte to a model organism in basic biology, biotechnology, and synthetic biology. Some of the key features of this system include a wide range of Omics technologies, precise genome-engineering via homologous recombination with yeast-like efficiency, a certified good-manufacturing-practice production in bioreactors, successful upscaling to 500 L wave reactors, excellent homogeneity of protein products, superb product stability from batch-to-batch, and a reliable procedure for cryopreservation of cell lines in a master cell bank. About a dozen human proteins are being produced in P. patens as potential biopharmaceuticals, some of them are not only similar to their animal-produced counterparts, but are real biobetters with superior performance. A moss-made pharmaceutical successfully passed phase 1 clinical trials, a fragrant moss, and a cosmetic moss-product is already on the market, highlighting the economic potential of this synthetic biology chassis. Here, we focus on the features of mosses as versatile cell factories for synthetic biology and their impact on metabolic engineering.
Collapse
Affiliation(s)
- Ralf Reski
- Plant Biotechnology, Faculty of Biology, University of Freiburg, 79104, Freiburg, Germany.
- BIOSS, Centre for Biological Signalling Studies, 79104, Freiburg, Germany.
| | - Hansol Bae
- Mosspiration Biotech IVS, 2970, Hørsholm, Denmark
| | - Henrik Toft Simonsen
- Mosspiration Biotech IVS, 2970, Hørsholm, Denmark
- Department of Biotechnology and Biomedicine, Technical University of Denmark, 2800 Kgs, Lyngby, Denmark
| |
Collapse
|
9
|
Abstract
Plant molecular farming depends on a diversity of plant systems for production of useful recombinant proteins. These proteins include protein biopolymers, industrial proteins and enzymes, and therapeutic proteins. Plant production systems include microalgae, cells, hairy roots, moss, and whole plants with both stable and transient expression. Production processes involve a narrowing diversity of bioreactors for cell, hairy root, microalgae, and moss cultivation. For whole plants, both field and automated greenhouse cultivation methods are used with products expressed and produced either in leaves or seeds. Many successful expression systems now exist for a variety of different products with a list of increasingly successful commercialized products. This chapter provides an overview and examples of the current state of plant-based production systems for different types of recombinant proteins.
Collapse
Affiliation(s)
| | - Thomas Bley
- Bioprocess Engineering, Institute of Food Technology and Bioprocess Engineering, TU Dresden, Dresden, Germany
| |
Collapse
|
10
|
Comparison of secretory signal peptides for heterologous protein expression in microalgae: Expanding the secretion portfolio for Chlamydomonas reinhardtii. PLoS One 2018; 13:e0192433. [PMID: 29408937 PMCID: PMC5800701 DOI: 10.1371/journal.pone.0192433] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Accepted: 01/22/2018] [Indexed: 12/22/2022] Open
Abstract
Efficient protein secretion is a desirable trait for any recombinant protein expression system, together with simple, low-cost, and defined media, such as the typical media used for photosynthetic cultures of microalgae. However, low titers of secreted heterologous proteins are usually obtained, even with the most extensively studied microalga Chlamydomonas reinhardtii, preventing their industrial application. In this study, we aimed to expand and evaluate secretory signal peptides (SP) for heterologous protein secretion in C. reinhardtii by comparing previously described SP with untested sequences. We compared the SPs from arylsulfatase 1 and carbonic anhydrase 1, with those of untried SPs from binding protein 1, an ice-binding protein, and six sequences identified in silico. We identified over 2000 unique SPs using the SignalP 4.0 software. mCherry fluorescence was used to compare the protein secretion of up to 96 colonies for each construct, non-secretion construct, and parental wild-type cc1690 cells. Supernatant fluorescence varied according to the SP used, with a 10-fold difference observed between the highest and lowest secretors. Moreover, two SPs identified in silico secreted the highest amount of mCherry. Our results demonstrate that the SP should be carefully selected and that efficient sequences can be coded in the C. reinhardtii genome. The SPs described here expand the portfolio available for research on heterologous protein secretion and for biomanufacturing applications.
Collapse
|
11
|
Hidalgo D, Abdoli-Nasab M, Jalali-Javaran M, Bru-Martínez R, Cusidó RM, Corchete P, Palazon J. Biotechnological production of recombinant tissue plasminogen activator protein (reteplase) from transplastomic tobacco cell cultures. PLANT PHYSIOLOGY AND BIOCHEMISTRY : PPB 2017; 118:130-137. [PMID: 28633085 DOI: 10.1016/j.plaphy.2017.06.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 06/09/2017] [Accepted: 06/12/2017] [Indexed: 05/22/2023]
Abstract
Transplastomic plants are a system of choice for the mass production of biopharmaceuticals due to the polyploidy of the plastid genome and the low risk of pollen-mediated outcrossing because of maternal inheritance. However, as field-grown plants, they can suffer contamination by agrochemicals and fertilizers, as well as fluctuations in yield due to climatic changes and infections. Tissue-type plasminogen activator (tPA), a protein used to treat heart attacks, converts plasminogen into plasmine, which digests fibrin and induces the dissolution of fibrin clots. Recently, we obtained transplastomic tobacco plants carrying the K2S gene encoding truncated human tPA (reteplase) with improved biological activity, and confirmed the presence of the target protein in the transgenic plant leaves. Considering the advantages of plant cell cultures for biopharmaceutical production, we established a cell line derived from the K2S tobacco plants. The active form of reteplase was quantified in cultures grown in light or darkness, with production 3-fold higher in light.
Collapse
Affiliation(s)
- Diego Hidalgo
- Laboratori de Fisiologia Vegetal, Facultat de Farmacia, Universitat de Barcelona, Av. Joan XXIII sn, 08028 Barcelona, Spain
| | - Maryam Abdoli-Nasab
- Department of Biotechnology, Institute of Science, High Technology and Environmental Science, Graduate University of Advanced Tecnology, P.O. Box 76315-117, Kerman, Iran
| | - Mokhtar Jalali-Javaran
- Department of Plant Breeding, Faculty of Agriculture, Tarbiat Modares University, P.O. Box 14115-336, Tehran, Iran
| | - Roque Bru-Martínez
- Plant Proteomics and Functional Genomics Group, Department of Agrochemistry and Biochemistry, Faculty of Science, University of Alicante, Alicante, Spain
| | - Rosa M Cusidó
- Laboratori de Fisiologia Vegetal, Facultat de Farmacia, Universitat de Barcelona, Av. Joan XXIII sn, 08028 Barcelona, Spain
| | - Purificación Corchete
- Department of Botany and Plant Physiology, Campus Miguel de Unamuno, University of Salamanca, E-37007, Salamanca, Spain
| | - Javier Palazon
- Laboratori de Fisiologia Vegetal, Facultat de Farmacia, Universitat de Barcelona, Av. Joan XXIII sn, 08028 Barcelona, Spain.
| |
Collapse
|
12
|
Fu W, Chaiboonchoe A, Khraiwesh B, Nelson DR, Al-Khairy D, Mystikou A, Alzahmi A, Salehi-Ashtiani K. Algal Cell Factories: Approaches, Applications, and Potentials. Mar Drugs 2016; 14:md14120225. [PMID: 27983586 PMCID: PMC5192462 DOI: 10.3390/md14120225] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 12/02/2016] [Accepted: 12/05/2016] [Indexed: 12/26/2022] Open
Abstract
With the advent of modern biotechnology, microorganisms from diverse lineages have been used to produce bio-based feedstocks and bioactive compounds. Many of these compounds are currently commodities of interest, in a variety of markets and their utility warrants investigation into improving their production through strain development. In this review, we address the issue of strain improvement in a group of organisms with strong potential to be productive “cell factories”: the photosynthetic microalgae. Microalgae are a diverse group of phytoplankton, involving polyphyletic lineage such as green algae and diatoms that are commonly used in the industry. The photosynthetic microalgae have been under intense investigation recently for their ability to produce commercial compounds using only light, CO2, and basic nutrients. However, their strain improvement is still a relatively recent area of work that is under development. Importantly, it is only through appropriate engineering methods that we may see the full biotechnological potential of microalgae come to fruition. Thus, in this review, we address past and present endeavors towards the aim of creating productive algal cell factories and describe possible advantageous future directions for the field.
Collapse
Affiliation(s)
- Weiqi Fu
- Division of Science and Math, New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| | - Amphun Chaiboonchoe
- Division of Science and Math, New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| | - Basel Khraiwesh
- Center for Genomics and Systems Biology (CGSB), New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| | - David R Nelson
- Center for Genomics and Systems Biology (CGSB), New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| | - Dina Al-Khairy
- Division of Science and Math, New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| | - Alexandra Mystikou
- Division of Science and Math, New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| | - Amnah Alzahmi
- Center for Genomics and Systems Biology (CGSB), New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| | - Kourosh Salehi-Ashtiani
- Division of Science and Math, New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
- Center for Genomics and Systems Biology (CGSB), New York University Abu Dhabi, P.O. Box 129188 Saadiyat Island, Abu Dhabi, UAE.
| |
Collapse
|
13
|
Mandal MK, Ahvari H, Schillberg S, Schiermeyer A. Tackling Unwanted Proteolysis in Plant Production Hosts Used for Molecular Farming. FRONTIERS IN PLANT SCIENCE 2016; 7:267. [PMID: 27014293 PMCID: PMC4782010 DOI: 10.3389/fpls.2016.00267] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Accepted: 02/19/2016] [Indexed: 05/17/2023]
Abstract
Although the field of molecular farming has significantly matured over the last years, some obstacles still need to be resolved. A major limiting factor for a broader application of plant hosts for the production of valuable recombinant proteins is the low yield of intact recombinant proteins. These low yields are at least in part due to the action of endogenous plant proteases on the foreign recombinant proteins. This mini review will present the current knowledge of the proteolytic enzymes involved in the degradation of different target proteins and strategies that are applied to suppress undesirable proteolytic activities in order to safeguard recombinant proteins during the production process.
Collapse
Affiliation(s)
| | | | | | - Andreas Schiermeyer
- Department of Plant Biotechnology, Fraunhofer Institute for Molecular Biology and Applied EcologyAachen, Germany
| |
Collapse
|
14
|
Santos RB, Abranches R, Fischer R, Sack M, Holland T. Putting the Spotlight Back on Plant Suspension Cultures. FRONTIERS IN PLANT SCIENCE 2016; 7:297. [PMID: 27014320 PMCID: PMC4786539 DOI: 10.3389/fpls.2016.00297] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 02/25/2016] [Indexed: 05/05/2023]
Abstract
Plant cell suspension cultures have several advantages that make them suitable for the production of recombinant proteins. They can be cultivated under aseptic conditions using classical fermentation technology, they are easy to scale-up for manufacturing, and the regulatory requirements are similar to those established for well-characterized production systems based on microbial and mammalian cells. It is therefore no surprise that taliglucerase alfa (Elelyso®)-the first licensed recombinant pharmaceutical protein derived from plants-is produced in plant cell suspension cultures. But despite this breakthrough, plant cells are still largely neglected compared to transgenic plants and the more recent plant-based transient expression systems. Here, we revisit plant cell suspension cultures and highlight recent developments in the field that show how the rise of plant cells parallels that of Chinese hamster ovary cells, currently the most widespread and successful manufacturing platform for biologics. These developments include medium optimization, process engineering, statistical experimental designs, scale-up/scale-down models, and process analytical technologies. Significant yield increases for diverse target proteins will encourage a gold rush to adopt plant cells as a platform technology, and the first indications of this breakthrough are already on the horizon.
Collapse
Affiliation(s)
- Rita B. Santos
- Plant Cell Biology Laboratory, Universidade Nova de Lisboa, Instituto de Tecnologia Química e Biológica António XavierOeiras, Portugal
| | - Rita Abranches
- Plant Cell Biology Laboratory, Universidade Nova de Lisboa, Instituto de Tecnologia Química e Biológica António XavierOeiras, Portugal
| | - Rainer Fischer
- Fraunhofer-Institut für Molekularbiologie und Angewandte Oekologie (IME), Integrated Production PlatformsAachen, Germany
- Biology VII, Institute for Molecular Biotechnology, RWTH Aachen UniversityAachen, Germany
| | - Markus Sack
- Biology VII, Institute for Molecular Biotechnology, RWTH Aachen UniversityAachen, Germany
| | - Tanja Holland
- Fraunhofer-Institut für Molekularbiologie und Angewandte Oekologie (IME), Integrated Production PlatformsAachen, Germany
- *Correspondence: Tanja Holland
| |
Collapse
|
15
|
Robert S, Goulet MC, D'Aoust MA, Sainsbury F, Michaud D. Leaf proteome rebalancing in Nicotiana benthamiana for upstream enrichment of a transiently expressed recombinant protein. PLANT BIOTECHNOLOGY JOURNAL 2015; 13:1169-79. [PMID: 26286859 DOI: 10.1111/pbi.12452] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2015] [Revised: 07/03/2015] [Accepted: 07/15/2015] [Indexed: 05/18/2023]
Abstract
A key factor influencing the yield of biopharmaceuticals in plants is the ratio of recombinant to host proteins in crude extracts. Postextraction procedures have been devised to enrich recombinant proteins before purification. Here, we assessed the potential of methyl jasmonate (MeJA) as a generic trigger of recombinant protein enrichment in Nicotiana benthamiana leaves before harvesting. Previous studies have reported a significant rebalancing of the leaf proteome via the jasmonate signalling pathway, associated with ribulose 1,5-bisphosphate carboxylase oxygenase (RuBisCO) depletion and the up-regulation of stress-related proteins. As expected, leaf proteome alterations were observed 7 days post-MeJA treatment, associated with lowered RuBisCO pools and the induction of stress-inducible proteins such as protease inhibitors, thionins and chitinases. Leaf infiltration with the Agrobacterium tumefaciens bacterial vector 24 h post-MeJA treatment induced a strong accumulation of pathogenesis-related proteins after 6 days, along with a near-complete reversal of MeJA-mediated stress protein up-regulation. RuBisCO pools were partly restored upon infiltration, but most of the depletion effect observed in noninfiltrated plants was maintained over six more days, to give crude protein samples with 50% less RuBisCO than untreated tissue. These changes were associated with net levels reaching 425 μg/g leaf tissue for the blood-typing monoclonal antibody C5-1 expressed in MeJA-treated leaves, compared to less than 200 μg/g in untreated leaves. Our data confirm overall the ability of MeJA to trigger RuBisCO depletion and recombinant protein enrichment in N. benthamiana leaves, estimated here for C5-1 at more than 2-fold relative to host proteins.
Collapse
Affiliation(s)
- Stéphanie Robert
- Centre de recherche et d'innovation sur les végétaux, Pavillon Envirotron, Université Laval, Québec, QC, Canada
| | - Marie-Claire Goulet
- Centre de recherche et d'innovation sur les végétaux, Pavillon Envirotron, Université Laval, Québec, QC, Canada
| | | | - Frank Sainsbury
- Centre de recherche et d'innovation sur les végétaux, Pavillon Envirotron, Université Laval, Québec, QC, Canada
- The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, St Lucia, QLD, Australia
| | - Dominique Michaud
- Centre de recherche et d'innovation sur les végétaux, Pavillon Envirotron, Université Laval, Québec, QC, Canada
| |
Collapse
|
16
|
Reski R, Parsons J, Decker EL. Moss-made pharmaceuticals: from bench to bedside. PLANT BIOTECHNOLOGY JOURNAL 2015; 13:1191-8. [PMID: 26011014 PMCID: PMC4736463 DOI: 10.1111/pbi.12401] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 04/16/2015] [Accepted: 04/17/2015] [Indexed: 05/10/2023]
Abstract
Over the past two decades, the moss Physcomitrella patens has been developed from scratch to a model species in basic research and in biotechnology. A fully sequenced genome, outstanding possibilities for precise genome-engineering via homologous recombination (knockout moss), a certified GMP production in moss bioreactors, successful upscaling to 500 L wave reactors, excellent homogeneity of protein glycosylation, remarkable batch-to-batch stability and a safe cryopreservation for master cell banking are some of the key features of the moss system. Several human proteins are being produced in this system as potential biopharmaceuticals. Among the products are tumour-directed monoclonal antibodies with enhanced antibody-dependent cytotoxicity (ADCC), vascular endothelial growth factor (VEGF), complement factor H (FH), keratinocyte growth factor (FGF7/KGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), asialo-erythropoietin (asialo-EPO, AEPO), alpha-galactosidase (aGal) and beta-glucocerebrosidase (GBA). Further, an Env-derived multi-epitope HIV protein as a candidate vaccine was produced, and first steps for a metabolic engineering of P. patens have been made. Some of the recombinant biopharmaceuticals from moss bioreactors are not only similar to those produced in mammalian systems such as CHO cells, but are of superior quality (biobetters). The first moss-made pharmaceutical, aGal to treat Morbus Fabry, is in clinical trials.
Collapse
Affiliation(s)
- Ralf Reski
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
- FRIAS - Freiburg Institute for Advanced Studies, Freiburg, Germany
- BIOSS - Centre for Biological Signalling Studies, Freiburg, Germany
| | - Juliana Parsons
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| | - Eva L Decker
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany
| |
Collapse
|
17
|
Orellana-Escobedo L, Rosales-Mendoza S, Romero-Maldonado A, Parsons J, Decker EL, Monreal-Escalante E, Moreno-Fierros L, Reski R. An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice. PLANT CELL REPORTS 2015; 34:425-433. [PMID: 25477207 DOI: 10.1007/s00299-014-1720-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Revised: 11/20/2014] [Accepted: 11/24/2014] [Indexed: 06/04/2023]
Abstract
The first report on the recombinant production of a candidate vaccine in the moss system. The need for economical and efficient platforms for vaccine production demands the exploration of emerging host organisms. In this study, the production of an antigenic protein is reported employing the moss Physcomitrella patens as an expression host. A multi-epitope protein from the Human Immunodeficiency Virus (HIV) based on epitopes from gp120 and gp41 was designed as a candidate subunit vaccine and named poly-HIV. Transgenic moss plants were generated carrying the corresponding poly-HIV transgene under a novel moss promoter and subsequently seven positive lines were confirmed by PCR. The poly-HIV protein accumulated up to 3.7 µg g(-1) fresh weight in protonema cultures. Antigenic and immunogenic properties of the moss-produced recombinant poly-HIV are evidenced by Western blots and by mice immunization assays. The elicitation of specific antibodies in mice was observed, reflecting the immunogenic potential of this moss-derived HIV antigen. This is the first report on the production of a potential vaccine in the moss system and opens the avenue for glycoengineering approaches for the production of HIV human-like glycosylated antigens as well as other vaccine prototypes under GMP conditions in moss bioreactors.
Collapse
Affiliation(s)
- Lucía Orellana-Escobedo
- Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, 78210, San Luis Potosí, SLP, Mexico,
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Müller K, Siegel D, Rodriguez Jahnke F, Gerrer K, Wend S, Decker EL, Reski R, Weber W, Zurbriggen MD. A red light-controlled synthetic gene expression switch for plant systems. MOLECULAR BIOSYSTEMS 2014; 10:1679-88. [PMID: 24469598 DOI: 10.1039/c3mb70579j] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
On command control of gene expression in time and space is required for the comprehensive analysis of key plant cellular processes. Even though some chemical inducible systems showing satisfactory induction features have been developed, they are inherently limited in terms of spatiotemporal resolution and may be associated with toxic effects. We describe here the first synthetic light-inducible system for the targeted control of gene expression in plants. For this purpose, we applied an interdisciplinary synthetic biology approach comprising mammalian and plant cell systems to customize and optimize a split transcription factor based on the plant photoreceptor phytochrome B and one of its interacting factors (PIF6). Implementation of the system in transient assays in tobacco protoplasts resulted in strong (95-fold) induction in red light (660 nm) and could be instantaneously returned to the OFF state by subsequent illumination with far-red light (740 nm). Capitalizing on this toggle switch-like characteristic, we demonstrate that the system can be kept in the OFF state in the presence of 740 nm-supplemented white light, opening up perspectives for future application of the system in whole plants. Finally we demonstrate the system's applicability in basic research, by the light-controlled tuning of auxin signalling networks in N. tabacum protoplasts, as well as its biotechnological potential for the chemical-inducer free production of therapeutic proteins in the moss P. patens.
Collapse
Affiliation(s)
- Konrad Müller
- Faculty of Biology, University of Freiburg, Schänzlestrasse 1, 79104 Freiburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Rosales-Mendoza S, Orellana-Escobedo L, Romero-Maldonado A, Decker EL, Reski R. The potential of Physcomitrella patens as a platform for the production of plant-based vaccines. Expert Rev Vaccines 2014; 13:203-12. [PMID: 24405402 DOI: 10.1586/14760584.2014.872987] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The moss Physcomitrella patens has a number of advantages for the production of biopharmaceuticals, including: i) availability of standardized conditions for cultivation in bioreactors; ii) not being part of the food chain; iii) high biosafety; iv) availability of highly efficient transformation methods; v) a haploid, fully sequenced genome providing genetic stability and uniform expression; vi) efficient gene targeting at the nuclear level allows for the generation of mutants with specific post-translational modifications (e.g., glycosylation patterns); and vii) oral formulations are a viable approach as no toxic effects are attributed to ingestion of this moss. In the light of this panorama, this opinion paper analyzes the possibilities of using P. patens for the production of oral vaccines and presents some specific cases where its use may represent significant progress in the field of plant-based vaccine development. The advantages represented by putative adjuvant effects of endogenous secondary metabolites and producing specific glycosylation patterns are highlighted.
Collapse
Affiliation(s)
- Sergio Rosales-Mendoza
- Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP, 78210, México
| | | | | | | | | |
Collapse
|
20
|
Decker EL, Parsons J, Reski R. Glyco-engineering for biopharmaceutical production in moss bioreactors. FRONTIERS IN PLANT SCIENCE 2014; 5:346. [PMID: 25071817 PMCID: PMC4089626 DOI: 10.3389/fpls.2014.00346] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Accepted: 06/27/2014] [Indexed: 05/02/2023]
Abstract
The production of recombinant biopharmaceuticals (pharmaceutical proteins) is a strongly growing area in the pharmaceutical industry. While most products to date are produced in mammalian cell cultures, namely Chinese hamster ovary cells, plant-based production systems gained increasing acceptance over the last years. Different plant systems have been established which are suitable for standardization and precise control of cultivation conditions, thus meeting the criteria for pharmaceutical production. The majority of biopharmaceuticals comprise glycoproteins. Therefore, differences in protein glycosylation between humans and plants have to be taken into account and plant-specific glycosylation has to be eliminated to avoid adverse effects on quality, safety, and efficacy of the products. The basal land plant Physcomitrella patens (moss) has been employed for the recombinant production of high-value therapeutic target proteins (e.g., Vascular Endothelial Growth Factor, Complement Factor H, monoclonal antibodies, Erythropoietin). Being genetically excellently characterized and exceptionally amenable for precise gene targeting via homologous recombination, essential steps for the optimization of moss as a bioreactor for the production of recombinant proteins have been undertaken. Here, we discuss the glyco-engineering approaches to avoid non-human N- and O-glycosylation on target proteins produced in moss bioreactors.
Collapse
Affiliation(s)
- Eva L. Decker
- Department of Plant Biotechnology, Faculty of Biology, University of FreiburgFreiburg, Germany
- *Correspondence: Eva L. Decker, Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Schaenzlestraße 1, 79104 Freiburg, Germany e-mail:
| | - Juliana Parsons
- Department of Plant Biotechnology, Faculty of Biology, University of FreiburgFreiburg, Germany
| | - Ralf Reski
- Department of Plant Biotechnology, Faculty of Biology, University of FreiburgFreiburg, Germany
- BIOSS Centre for Biological Signalling StudiesFreiburg, Germany
- Freiburg Institute for Advanced StudiesFreiburg, Germany
| |
Collapse
|
21
|
Lehtonen MT, Takikawa Y, Rönnholm G, Akita M, Kalkkinen N, Ahola-Iivarinen E, Somervuo P, Varjosalo M, Valkonen JPT. Protein secretome of moss plants (Physcomitrella patens) with emphasis on changes induced by a fungal elicitor. J Proteome Res 2013; 13:447-59. [PMID: 24295333 DOI: 10.1021/pr400827a] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Studies on extracellular proteins (ECPs) contribute to understanding of the multifunctional nature of apoplast. Unlike vascular plants (tracheophytes), little information about ECPs is available from nonvascular plants, such as mosses (bryophytes). In this study, moss plants (Physcomitrella patens) were grown in liquid culture and treated with chitosan, a water-soluble form of chitin that occurs in cell walls of fungi and insects and elicits pathogen defense in plants. ECPs released to the culture medium were compared between chitosan-treated and nontreated control cultures using quantitative mass spectrometry (Orbitrap) and 2-DE-LC-MS/MS. Over 400 secreted proteins were detected, of which 70% were homologous to ECPs reported in tracheophyte secretomes. Bioinformatics analyses using SignalP and SecretomeP predicted classical signal peptides for secretion (37%) or leaderless secretion (27%) for most ECPs of P. patens, but secretion of the remaining proteins (36%) could not be predicted using bioinformatics. Cultures treated with chitosan contained 72 proteins not found in untreated controls, whereas 27 proteins found in controls were not detected in chitosan-treated cultures. Pathogen defense-related proteins dominated in the secretome of P. patens, as reported in tracheophytes. These results advance knowledge on protein secretomes of plants by providing a comprehensive account of ECPs of a bryophyte.
Collapse
Affiliation(s)
- Mikko T Lehtonen
- Department of Agricultural Sciences, University of Helsinki , PO Box 27, FI-00014 Helsinki, Finland
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Holland T, Blessing D, Hellwig S, Sack M. The in-line measurement of plant cell biomass using radio frequency impedance spectroscopy as a component of process analytical technology. Biotechnol J 2013; 8:1231-40. [PMID: 24039008 DOI: 10.1002/biot.201300125] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 06/05/2013] [Accepted: 07/18/2013] [Indexed: 01/20/2023]
Abstract
Radio frequency impedance spectroscopy (RFIS) is a robust method for the determination of cell biomass during fermentation. RFIS allows non-invasive in-line monitoring of the passive electrical properties of cells in suspension and can distinguish between living and dead cells based on their distinct behavior in an applied radio frequency field. We used continuous in situ RFIS to monitor batch-cultivated plant suspension cell cultures in stirred-tank bioreactors and compared the in-line data to conventional off-line measurements. RFIS-based analysis was more rapid and more accurate than conventional biomass determination, and was sensitive to changes in cell viability. The higher resolution of the in-line measurement revealed subtle changes in cell growth which were not accessible using conventional methods. Thus, RFIS is well suited for correlating such changes with intracellular states and product accumulation, providing unique opportunities for employing systems biotechnology and process analytical technology approaches to increase product yield and quality.
Collapse
Affiliation(s)
- Tanja Holland
- Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany.
| | | | | | | |
Collapse
|
23
|
Parsons J, Altmann F, Arrenberg CK, Koprivova A, Beike AK, Stemmer C, Gorr G, Reski R, Decker EL. Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants. PLANT BIOTECHNOLOGY JOURNAL 2012; 10:851-61. [PMID: 22621344 DOI: 10.1111/j.1467-7652.2012.00704.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Protein therapeutics represent one of the most increasing areas in the pharmaceutical industry. Plants gain acceptance as attractive alternatives for high-quality and economical protein production. However, as the majority of biopharmaceuticals are glycoproteins, plant-specific N-glycosylation has to be taken into consideration. In Physcomitrella patens (moss), glyco-engineering is an applicable tool, and the removal of immunogenic core xylose and fucose residues was realized before. Here, we present the identification of the enzymes that are responsible for terminal glycosylation (α1,4 fucosylation and β1,3 galactosylation) on complex-type N-glycans in moss. The terminal trisaccharide consisting of α1,4 fucose and β1,3 galactose linked to N-acetylglucosamine forms the so-called Lewis A epitope. This epitope is rare on moss wild-type proteins, but was shown to be enriched on complex-type N-glycans of moss-produced recombinant human erythropoietin, while unknown from the native human protein. Via gene targeting of moss galactosyltransferase and fucosyltransferase genes, we identified the gene responsible for terminal glycosylation and were able to completely abolish the formation of Lewis A residues on the recombinant biopharmaceutical.
Collapse
Affiliation(s)
- Juliana Parsons
- Plant Biotechnology, University of Freiburg, Freiburg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Decker EL, Reski R. Glycoprotein production in moss bioreactors. PLANT CELL REPORTS 2012; 31:453-60. [PMID: 21960098 DOI: 10.1007/s00299-011-1152-5] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Revised: 09/05/2011] [Accepted: 09/11/2011] [Indexed: 05/23/2023]
Abstract
Complex multimeric recombinant proteins such as therapeutic antibodies require a eukaryotic expression system. Transgenic plants may serve as promising alternatives to the currently favored mammalian cell lines or hybridomas. In contrast to prokaryotic systems, posttranslational modifications of plant and human proteins resemble each other largely, among those, protein N-glycosylation of the complex type. However, a few plant-specific sugar residues may cause immune reactions in humans, representing an obstacle for the broad use of plant-based systems as biopharmaceutical production hosts. The moss Physcomitrella patens represents a flexible tissue-culture system for the contained production and secretion of recombinant biopharmaceuticals in photobioreactors. The recent synthesis of therapeutic proteins as a scFv antibody fragment or the large and heavily modified complement regulator factor H demonstrate the versatility of this expression system. A uniquely efficient gene targeting mechanism can be employed to precisely engineer the glycosylation machinery for recombinant products. In this way, P. patens lines with non-immunogenic optimized glycan structures were created. Therapeutic antibodies produced in these strains exhibited antibody-dependent cellular cytotoxicity superior to the same molecules synthesized in mammalian cell lines.
Collapse
Affiliation(s)
- Eva L Decker
- Plant Biotechnology, University of Freiburg, Schaenzlestr. 1, 79104 Freiburg, Germany
| | | |
Collapse
|
25
|
Cerff M, Posten C. Relationship between light intensity and morphology of the moss Physcomitrella patens in a draft tube photo bioreactor. Biochem Eng J 2012. [DOI: 10.1016/j.bej.2011.10.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Cerff M, Posten C. Enhancing the growth of Physcomitrella patens by combination of monochromatic red and blue light - a kinetic study. Biotechnol J 2011; 7:527-36. [DOI: 10.1002/biot.201100044] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2011] [Revised: 05/07/2011] [Accepted: 06/06/2011] [Indexed: 11/10/2022]
|
27
|
Büttner-Mainik A, Parsons J, Jérôme H, Hartmann A, Lamer S, Schaaf A, Schlosser A, Zipfel PF, Reski R, Decker EL. Production of biologically active recombinant human factor H in Physcomitrella. PLANT BIOTECHNOLOGY JOURNAL 2011; 9:373-83. [PMID: 20723134 DOI: 10.1111/j.1467-7652.2010.00552.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
The human complement regulatory serum protein factor H (FH) is a promising future biopharmaceutical. Defects in the gene encoding FH are associated with human diseases like severe kidney and retinal disorders in the form of atypical haemolytic uremic syndrome (aHUS), membranoproliferative glomerulonephritis II (MPGN II) or age-related macular degeneration (AMD). There is a current need to apply intact full-length FH for the therapy of patients with congenital or acquired defects of this protein. Application of purified or recombinant FH (rFH) to these patients is an important and promising approach for the treatment of these diseases. However, neither protein purified from plasma of healthy individuals nor recombinant protein is currently available on the market. Here, we report the first stable expression of the full-length human FH cDNA and the subsequent production of this glycoprotein in a plant system. The moss Physcomitrella patens perfectly suits the requirements for the production of complex biopharmaceuticals as this eukaryotic system not only offers an outstanding genetical accessibility, but moreover, proteins can be produced safely in scalable photobioreactors without the need for animal-derived medium compounds. Transgenic moss lines were created, which express the human FH cDNA and target the recombinant protein to the culture supernatant via a moss-derived secretion signal. Correct processing of the signal peptide and integrity of the moss-produced rFH were verified via peptide mapping by mass spectrometry. Ultimately, we show that the rFH displays complement regulatory activity comparable to FH purified from plasma.
Collapse
|
28
|
Holland T, Sack M, Rademacher T, Schmale K, Altmann F, Stadlmann J, Fischer R, Hellwig S. Optimal nitrogen supply as a key to increased and sustained production of a monoclonal full-size antibody in BY-2 suspension culture. Biotechnol Bioeng 2010; 107:278-89. [PMID: 20506104 DOI: 10.1002/bit.22800] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Plant cell cultures have been used as expression hosts for recombinant proteins for over two decades. The quality of plant cell culture-produced proteins such as full-size monoclonal antibodies has been shown to be excellent in terms of protein folding and binding activity, but the productivity and yield fell short of what was achieved using mammalian cell culture, in which the key to gram-per-liter expression levels was strain selection and medium/process optimization. We carried out an extensive media analysis and optimization for the production of the full-size human anti-HIV antibody 2G12 in N. tabacum cv. BY-2. Nitrogen source and availability was found to be one key factor for the volumetric productivity of plant cell cultures. Increased amounts of nitrate in the culture medium had a dramatic impact on protein yields, resulting in a 10-20-fold increase in product accumulation through a combination of enhanced secretion and higher stability. The results were scalable from shake flasks to stirred-tank bioreactors, where the maximum yield per cultivation volume was 8 mg L(-1) over 7 days. During the stationary phase, antibody levels were 150-fold higher in nitrogen-enriched medium compared to standard medium. The enhanced medium appeared not to affect antibody quality and activity, as determined by Western blots, surface plasmon resonance binding assays and N-glycan analysis.
Collapse
Affiliation(s)
- T Holland
- Fraunhofer Institute for Molecular Biology and Applied Ecology, Forckenbeckstrasse 6, 52074 Aachen, Germany
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Huang TK, Plesha MA, Falk BW, Dandekar AM, McDonald KA. Bioreactor strategies for improving production yield and functionality of a recombinant human protein in transgenic tobacco cell cultures. Biotechnol Bioeng 2009; 102:508-20. [PMID: 18767186 DOI: 10.1002/bit.22061] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Plant cell culture production of recombinant products offers a number of advantages over traditional eukaryotic expression systems, particularly if the product can be targeted to and purified from the cell culture broth. However, one of the main obstacles is product degradation by proteases that are produced during cell culture, and/or the loss of biological activity of secreted (extracellular) products as a result of alteration in the protein conformation. Because proteolysis activity and target protein stability can be significantly influenced by culture conditions, it is important to evaluate bioprocess conditions that minimize these effects. In this study, a bioreactor strategy using a protocol involving pH adjustment and medium exchange during plant cell culture is proposed for improving the production of functional recombinant alpha(1)-antitrypsin (rAAT), a human blood protein, produced using several alternative expression systems, including a Cauliflower mosaic virus (CaMV) 35S constitutive promoter expression system, a chemically inducible, estrogen receptor-based promoter (XVE) expression system, and a novel Cucumber mosaic virus (CMV) inducible viral amplicon (CMViva) expression system developed by our group. We have demonstrated that higher medium pH help reduce protease activity derived from cell cultures and improve the inherent stability of human AAT protein as well. This strategy resulted in a fourfold increase in the productivity of extracellular functional rAAT (100 microg/L) and a twofold increase in the ratio of functional rAAT to total rAAT (48%) in transgenic N. benthamiana cell cultures using a chemically inducible viral amplicon expression system.
Collapse
Affiliation(s)
- Ting-Kuo Huang
- Department of Chemical Engineering and Materials Science, University of California, Davis, 1 Shields Avenue, Davis, California 95616, USA
| | | | | | | | | |
Collapse
|
30
|
Sourrouille C, Marshall B, Liénard D, Faye L. From Neanderthal to nanobiotech: from plant potions to pharming with plant factories. Methods Mol Biol 2009; 483:1-23. [PMID: 19183890 DOI: 10.1007/978-1-59745-407-0_1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Plants were the main source for human drugs until the beginning of the nineteenth century when plant-derived pharmaceuticals were partly supplanted by drugs produced by the industrial methods of chemical synthesis. During the last decades of the twentieth century, genetic engineering has offered an alternative to chemical synthesis, using bacteria, yeasts and animal cells as factories for the production of therapeutic proteins. After a temporary decrease in interest, plants are rapidly moving back into human pharmacopoeia, with the recent development of plant-based recombinant protein production systems offering a safe and extremely cost-effective alternative to microbial and mammalian cell cultures. In this short review, we will illustrate that current improvements in plant expression systems are making them suitable as alternative factories for the production of either simple or highly complex therapeutic proteins.
Collapse
|
31
|
Gitzinger M, Parsons J, Reski R, Fussenegger M. Functional cross-kingdom conservation of mammalian and moss (Physcomitrella patens) transcription, translation and secretion machineries. PLANT BIOTECHNOLOGY JOURNAL 2009; 7:73-86. [PMID: 19021876 DOI: 10.1111/j.1467-7652.2008.00376.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Plants and mammals are separated by a huge evolutionary distance. Consequently, biotechnology and genetics have traditionally been divided into 'green' and 'red'. Here, we provide comprehensive evidence that key components of the mammalian transcription, translation and secretion machineries are functional in the model plant Physcomitrella patens. Cross-kingdom compatibility of different expression modalities originally designed for mammalian cells, such as native and synthetic promoters and polyadenylation sites, viral and cellular internal ribosome entry sites, secretion signal peptides and secreted product proteins, and synthetic transactivators and transrepressors, was established. This mammalian expression portfolio enabled constitutive, conditional and autoregulated expression of different product genes in a multicistronic expression format, optionally adjusted by various trigger molecules, such as butyrolactones, macrolide antibiotics and ethanol. Capitalizing on a cross-kingdom-compatible expression platform, we pioneered a prototype biopharmaceutical manufacturing scenario using microencapsulated transgenic P. patens protoplasts cultivated in a Wave Bioreactor. Vascular endothelial growth factor 121 (VEGF(121)) titres matched those typically achieved by standard protonema populations grown in stirred-tank bioreactors. The full compatibility of mammalian expression systems in P. patens further promotes the use of moss as a cost-effective alternative for the manufacture of complex biopharmaceuticals, and as a valuable host system to advance synthetic biology in plants.
Collapse
Affiliation(s)
- Marc Gitzinger
- Department for Biosystems Science and Engineering, ETH Zurich, Wolfgang-Pauli-Strasse 10, HCI F115, CH-8093 Zurich, Switzerland
| | | | | | | |
Collapse
|
32
|
Decker EL, Reski R. Moss bioreactors producing improved biopharmaceuticals. Curr Opin Biotechnol 2007; 18:393-8. [PMID: 17869503 DOI: 10.1016/j.copbio.2007.07.012] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2007] [Revised: 07/25/2007] [Accepted: 07/26/2007] [Indexed: 11/20/2022]
Abstract
Plants may serve as superior production systems for complex recombinant pharmaceuticals. Current strategies for improving plant-based systems include the development of large-scale production facilities as well as the optimisation of protein modifications. While post-translational modifications of plant proteins generally resemble those of mammalian proteins, certain plant-specific protein-linked sugars are immunogenic in humans, a fact that restricts the use of plants in biopharmaceutical production so far. The moss Physcomitrella patens was developed as a contained tissue culture system for recombinant protein production in photo-bioreactors. By targeted gene replacements, moss strains were created with non-immunogenic humanised glycan patterns. These were proven to be superior to currently used mammalian cell lines in producing antibodies with enhanced effectiveness.
Collapse
Affiliation(s)
- Eva L Decker
- Plant Biotechnology, Faculty of Biology, University of Freiburg, Schaenzlestr. 1, D-79104 Freiburg, Germany
| | | |
Collapse
|
33
|
Abstract
This review examines the challenges of segregating biopharmed crops expressing pharmaceutical or veterinary agents from mainstream crops, particularly those destined for food or feed use. The strategy of using major food crops as production vehicles for the expression of pharmaceutical or veterinary agents is critically analysed in the light of several recent episodes of contamination of the human food chain by non-approved crop varieties. Commercially viable strategies to limit or avoid biopharming intrusion into the human food chain require the more rigorous segregation of food and non-food varieties of the same crop species via a range of either physical or biological methods. Even more secure segregation is possible by the use of non-food crops, non-crop plants or in vitro plant cultures as production platforms for biopharming. Such platforms already under development range from outdoor-grown Nicotiana spp. to glasshouse-grown Arabidopsis, lotus and moss. Amongst the more effective methods for biocontainment are the plastid expression of transgenes, inducible and transient expression systems, and physical containment of plants or cell cultures. In the current atmosphere of heightened concerns over food safety and biosecurity, the future of biopharming may be largely determined by the extent to which the sector is able to maintain public confidence via a more considered approach to containment and security of its plant production systems.
Collapse
Affiliation(s)
- Denis J Murphy
- Biotechnology Unit, Division of Biological Sciences, University of Glamorgan, Treforest, CF37 1DL, UK.
| |
Collapse
|
34
|
Decker EL, Reski R. Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Bioprocess Biosyst Eng 2007; 31:3-9. [PMID: 17701058 DOI: 10.1007/s00449-007-0151-y] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Accepted: 07/26/2007] [Indexed: 01/07/2023]
Abstract
Transgenic plants are promising alternatives for the low-cost and safe pathogen-free production of complex recombinant pharmaceutical proteins (molecular farming). Plants as higher eukaryotes perform posttranslational modifications similar to those of mammalian cells. However, plant-specific protein N-glycosylation was shown to be immunogenic, a fact that represents a drawback for many plant systems in biopharmaceutical production. The moss Physcomitrella patens offers unique properties as a contained system for protein production. It is grown in the predominant haploid gametophytic stage as tissue suspension cultures in photobioreactors. Efficient secretory signals and a transient transfection system allow the secretion of freshly synthesized proteins to the surrounding medium. The key advantage of Physcomitrella compared to other plant systems is the feasibility of targeted gene replacements. By this means, moss strains with non-immunogenic humanized glycan patterns were created. Here we present an overview of the relevant aspects for establishing moss as a production system for recombinant biopharmaceuticals.
Collapse
Affiliation(s)
- Eva L Decker
- Plant Biotechnology, Faculty of Biology, Freiburg University, Schaenzlestr. 1, 79104 Freiburg, Germany.
| | | |
Collapse
|
35
|
Weise A, Altmann F, Rodriguez-Franco M, Sjoberg ER, Bäumer W, Launhardt H, Kietzmann M, Gorr G. High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Delta-fuc-t Delta-xyl-t mutant. PLANT BIOTECHNOLOGY JOURNAL 2007; 5:389-401. [PMID: 17359496 DOI: 10.1111/j.1467-7652.2007.00248.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
The highly glycosylated peptide hormone erythropoietin (EPO) plays a key role in the regulation of erythrocyte maturation. Currently, marketed EPO is produced by recombinant technology in mammalian cell cultures. The complementary DNA (cDNA) for human EPO (hEPO) was transiently and stably expressed in the moss Physcomitrella patens wild-type and Delta-fuc-t Delta-xyl-t mutant, the latter containing N-glycans lacking the plant-specific, core-bound alpha1,3-fucose and beta1,2-xylose. New expression vectors were designed based on a Physcomitrella ubiquitin gene-derived promoter for the expression of hEPO cDNA. Transient expression in protoplasts was much stronger at 10 than at 20 degrees C. In Western blot analysis, the molecular size of moss-produced recombinant human EPO (rhEPO) was identified to be 30 kDa, and it accumulated in the medium of transiently transformed protoplasts to high levels around 0.5 microg/mL. Transgenic Physcomitrella Delta-fuc-t Delta-xyl-t mutant lines expressing EPO cDNA showed secretion of rhEPO through the cell wall to the culture medium. In 5- and 10-L photobioreactor cultures, secreted rhEPO accumulated to high levels above 250 microg/g dry weight of moss material after 6 days. Silver staining of rhEPO on sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) taken from the bioreactor culture demonstrated a high purity of the over-expressed secreted rhEPO, with a very low background of endogenous moss proteins. Peptide mapping of rhEPO produced by the Physcomitrella Delta-fuc-t Delta-xyl-t mutant indicated correct processing of the plant-derived signal peptide. All three N-glycosylation sites of rhEPO were occupied by complex-type N-glycans completely devoid of the plant-specific core sugar residues fucose and xylose.
Collapse
Affiliation(s)
- Andreas Weise
- Greenovation Biotech GmbH, Bötzingerstr. 29b, D-79111 Freiburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Liénard D, Sourrouille C, Gomord V, Faye L. Pharming and transgenic plants. BIOTECHNOLOGY ANNUAL REVIEW 2007; 13:115-47. [PMID: 17875476 DOI: 10.1016/s1387-2656(07)13006-4] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Plant represented the essence of pharmacopoeia until the beginning of the 19th century when plant-derived pharmaceuticals were partly supplanted by drugs produced by the industrial methods of chemical synthesis. In the last decades, genetic engineering has offered an alternative to chemical synthesis, using bacteria, yeasts and animal cells as factories for the production of therapeutic proteins. More recently, molecular farming has rapidly pushed towards plants among the major players in recombinant protein production systems. Indeed, therapeutic protein production is safe and extremely cost-effective in plants. Unlike microbial fermentation, plants are capable of carrying out post-translational modifications and, unlike production systems based on mammalian cell cultures, plants are devoid of human infective viruses and prions. Furthermore, a large panel of strategies and new plant expression systems are currently developed to improve the plant-made pharmaceutical's yields and quality. Recent advances in the control of post-translational maturations in transgenic plants will allow them, in the near future, to perform human-like maturations on recombinant proteins and, hence, make plant expression systems suitable alternatives to animal cell factories.
Collapse
Affiliation(s)
- David Liénard
- Université de Rouen, CNRS UMR 6037, IFRMP 23, GDR 2590, Faculté des Sciences, Bât. Ext. Biologie, 76821 Mont-Saint-Aignan cedex, France
| | | | | | | |
Collapse
|
37
|
Roessner U, Pettolino F. The importance of anatomy and physiology in plant metabolomics. TOPICS IN CURRENT GENETICS 2007. [DOI: 10.1007/4735_2007_0218] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
38
|
Lucumi A, Posten C. Establishment of long-term perfusion cultures of recombinant moss in a pilot tubular photobioreactor. Process Biochem 2006. [DOI: 10.1016/j.procbio.2006.06.017] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Doran PM. Foreign protein degradation and instability in plants and plant tissue cultures. Trends Biotechnol 2006; 24:426-32. [PMID: 16843560 DOI: 10.1016/j.tibtech.2006.06.012] [Citation(s) in RCA: 157] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2005] [Accepted: 06/29/2006] [Indexed: 11/27/2022]
Abstract
Low production cost is a key factor driving the development of plants and plant tissue cultures for the synthesis of therapeutic and other foreign proteins. Because product yield and concentration exert a major influence on process economics, improving foreign protein accumulation is crucial for enhancing the commercial success of plant-based production systems. Strategies aimed at increasing transgene expression have been effective; however, a critical but poorly understood factor contributing to low foreign protein yield is post-synthesis and/or post-secretion instability and degradation. Loss of foreign protein as result of biological and physical processes such as proteolytic destruction and irreversible surface adsorption can occur in plants and plant culture systems. This review highlights the need to consider such mechanisms and outlines a range of remedial strategies aimed at minimizing foreign protein degradation and loss.
Collapse
Affiliation(s)
- Pauline M Doran
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
| |
Collapse
|
40
|
Kermode AR. Plants as factories for production of biopharmaceutical and bioindustrial proteins: lessons from cell biologyThis review is one of a selection of papers published in the Special Issue on Plant Cell Biology. ACTA ACUST UNITED AC 2006. [DOI: 10.1139/b06-069] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Transgenic plants, seeds, and cultured plant cells are potentially one of the most economical systems for large-scale production of recombinant proteins for industrial and pharmaceutical uses. Biochemical, technical, and economic concerns with current production systems have generated enormous interest in developing plants as alternative production systems. However, various challenges must be met before plant systems can fully emerge as suitable, viable alternatives to current animal-based systems for large-scale production of biopharmaceuticals and other products. Aside from regulatory issues and developing efficient methods for downstream processing of recombinant proteins, there are at least two areas of challenge: (1) Can we engineer plant cells to accumulate recombinant proteins to sufficient levels? (2) Can we engineer plant cells to post-translationally modify recombinant proteins so that they are structurally and functionally similar to the native proteins? Attempts to improve the accumulation of a recombinant protein in plant cells require an appreciation of the processes of gene transcription, mRNA stability, processing, and export, and translation initiation and efficiency. Likewise, many post-translational factors must be considered, including protein stability, protein function and activity, and protein targeting. Moreover, we need to understand how the various processes leading from the gene to the functional protein are interdependent and functionally linked. Manipulation of the post-translational processing machinery of plant cells, especially that for N-linked glycosylation and glycan processing, is a challenging and exciting area. The functions of N-glycan heterogeneity and microheterogeneity, especially with respect to protein function, stability, and transport, are poorly understood and this represents an important area of cell biology.
Collapse
Affiliation(s)
- Allison R. Kermode
- Department of Biological Sciences, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 1S6, Canada (e-mail: )
| |
Collapse
|
41
|
Schaaf A, Tintelnot S, Baur A, Reski R, Gorr G, Decker EL. Use of endogenous signal sequences for transient production and efficient secretion by moss (Physcomitrella patens) cells. BMC Biotechnol 2005; 5:30. [PMID: 16271156 PMCID: PMC1291358 DOI: 10.1186/1472-6750-5-30] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2005] [Accepted: 11/07/2005] [Indexed: 11/10/2022] Open
Abstract
Background Efficient targeting to appropriate cell organelles is one of the bottlenecks for the production of recombinant proteins in plant systems. A common practice is to use the native secretory signal peptide of the heterologous protein to be produced. Though general features of secretion signals are conserved between plants and animals, the broad sequence variability among signal peptides suggests differing efficiency of signal peptide recognition. Results Aiming to improve secretion in moss bioreactors, we quantitatively compared the efficiency of two human signal peptides and six signals from recently isolated moss (Physcomitrella patens) proteins. We therefore used fusions of the different signals to heterologous reporter sequences for transient transfection of moss cells and measured the extra- and intracellular accumulation of the recombinant proteins rhVEGF and GST, respectively. Our data demonstrates an up to fivefold higher secretion efficiency with endogenous moss signals compared to the two utilised human signal peptides. Conclusion From the distribution of extra- and intracellular recombinant proteins, we suggest translational inhibition during the signal recognition particle-cycle (SRP-cycle) as the most probable of several possible explanations for the decreased extracellular accumulation with the human signals. In this work, we report on the supremacy of moss secretion signals over the utilised heterologous ones within the moss-bioreactor system. Though the molecular details of this effect remain to be elucidated, our results will contribute to the improvement of molecular farming systems.
Collapse
Affiliation(s)
- Andreas Schaaf
- Department of Plant Biochemistry and Biotechnology, University of Münster, Hindenburgplatz 55, 48143 Münster, Germany
| | - Stefanie Tintelnot
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Schaenzlestr. 1, 79104 Freiburg, Germany
| | - Armin Baur
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Schaenzlestr. 1, 79104 Freiburg, Germany
- greenovation Biotech GmbH, Boetzinger Str. 29b, 79111 Freiburg, Germany
| | - Ralf Reski
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Schaenzlestr. 1, 79104 Freiburg, Germany
| | - Gilbert Gorr
- greenovation Biotech GmbH, Boetzinger Str. 29b, 79111 Freiburg, Germany
| | - Eva L Decker
- Department of Plant Biotechnology, Faculty of Biology, University of Freiburg, Schaenzlestr. 1, 79104 Freiburg, Germany
| |
Collapse
|
42
|
Weise A, Rodriguez-Franco M, Timm B, Hermann M, Link S, Jost W, Gorr G. Use of Physcomitrella patens actin 5' regions for high transgene expression: importance of 5' introns. Appl Microbiol Biotechnol 2005; 70:337-45. [PMID: 16059684 DOI: 10.1007/s00253-005-0087-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2005] [Revised: 07/02/2005] [Accepted: 07/03/2005] [Indexed: 11/28/2022]
Abstract
We have isolated four actin (Act) genes from Physcomitrella patens and used their corresponding 5' regions for recombinant expression of the human vascular endothelial growth factor (rhVEGF121) in transiently transformed Physcomitrella protoplasts and in stable transformed lines. In the transient system, we found up to 11-fold activity of the corresponding 5' regions as compared with that of the plant constitutive 35S promoter. Moreover, the use of an optimised expression vector in which the human VEGF signal peptide was exchanged with a plant signal peptide resulted in an additional 7-fold increase in secreted rhVEGF. We found that the 5' introns of PpAct1, PpAct5 and PpAct7 are essential for high expression. The enhancing mechanisms of the introns, however, seem to be different since in the case of PpAct1, the expression level is stimulated only in the presence of the endogenous promoter, whereas the 5' introns of PpAct5 and PpAct7 stimulate expression also in combination with the 35S promoter. Beyond this, the isolated 5' regions are shown to be useful for high expression levels in transgenic moss lines with values of secreted rhVEGF up to 96 microg g(-1) dry weight.
Collapse
Affiliation(s)
- Andreas Weise
- greenovation Biotech GmbH, Bötzinger Str. 29b, 79111, Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|